Objective 1 definition
Objective 1. At least ninety percent (90%) of clients shall rate services as satisfactory.
Objective 1. Negative population trend reversed to positive.
Objective 1. At least ninety percent (90%) of clients shall rate services as satisfactory. In consideration of the services provided by Contractor in Exhibit A, County shall pay Contractor based on the following fee schedule:
Examples of Objective 1 in a sentence
Objective 1: At least ninety percent (90%) of customer survey respondents will rate services as good or better.
Objective 1: Individual service installation; and, Objective 2: Successful Install Monthly Percentage by service type.
Objective 2: Successful Install Monthly Percentage per Service: Rights and Remedies Per Occurrence: Objective 1: Individual Service Requests: 50 percent of installation fee credited to Customer for any missed committed objective.
Objective 1: Contractor shall involve each child's family in the treatment process.
Objective: 1: At least ninety percent (90%) of respondents will agree or strongly agree that they are satisfied with serviced received.
More Definitions of Objective 1
Objective 1. Assess cell viability of synthetic uttroside B, compared to plant Uttroside B, sorafenib and regorafenib Cell Viability Study: Synthetic Uttroside B will be assessed in various hepatocellular carcinoma (HCC) cell lines to assess cell viabilities associated with synthetic Uttroside B treatment, and compared to sorafenib and regorafenib. The goal is to assess the efficacy of synthetic uttroside B, compared to plant extract Uttroside B, as well as sorafenib (the current drug for HCC), and Regorafenib – stivarga, which is currently in clinical trial and seems to be promising compared to sorafenib. HCC pre-clinical orthotopic and transgenic models: The orthotopic Huh7 HCC xenograft model will be used in Objective 2 to assess the efficacy of synthetic uttroside B, and compared to both sorafenib and Regorafenib. Objective 2: Assess the efficacy of synthetic uttroside B in pre-clinical orthotopic mouse models for HCC (HuH7 orthotopic xenograft model in nude mice), using MR imaging techniques. MRI diagnosis of HCC: MRI is considered to be superior to computed tomography (CT) in detecting HCC tumors due to its improved contrast resolution and tissue characterization. In addition, the MRI method diffusion- weighted imaging (DWI), which assesses tissue structural alterations associated with disease pathology, can be used to detect early treatment response that correlates well with necrosis, by measuring ADC (apparent diffusion coefficient) values. Both contrast-enhanced MRI and DWI will be used in Objective 2 to assess the efficacy of synthetic uttroside B. HCC pre-clinical orthotopic model: We will use an orthotopic xenograft model (HuH7 cell-derived tumor tissue in Balb/c nude mice) for the in vivo studies. Synthetic uttroside B will be compared to Regorafenib and sorafenib, as well as untreated tumor-bearing animals. Following intrahepatic cell implantations, mice will be imaged by contrast-enhanced MRI (CE-MRI) (7 Tesla 30-cm horizontal-bore magnet) to assess tumor growth. Once tumors reach 10-20 mm3 in volumes, mice will be separated into 4 groups (untreated (5 mice), or treated with either synthetic uttroside B (10 mg/kg 3x/week i.v.; 10 mice), sorafenib (5 mice) or Regorafenib (10 mice)). Over the course of 6-8 weeks, mice will be imaged by CE-MRI to calculate tumor volumes, and by DWI to assess ADC values that will be a quantitative measure of tissue structural alterations from tumor growth and treatment response. Tumor tissue samples from tumor-bearing animal...
Objective 1. [Insert first project objective] [Make duplicate copies of this Section 2.1.1 as needed] The following table sets forth the supported tasks, their durations and costs. Task 1.2 Task 1.3
Objective 1. Conduct general grant administration and deliver a project research or outreach plan, required meetings, quarterly and annual progress reports, invoices, and a final report.
Objective 1. Improve student literacy skills (K-12) with a focus on reading achievement Performance Indicators Performance Target Summary of Progress Performance Target
Objective 1. Proactively raise awareness of the project results through Web and social media, publications (conferences and journals), organisation of workshops, summer schools (SenZations and ENoLL) and participation in the IoT cluster concentration meetings. • Objective 2: Contribute to IoT Labs activities and events.
Objective 1. ADDED Objective 2.1: Complete GLP-toxicology study in NHPs. Utilizing the material produced by CMO/Partner in Year 1, the Company’s Preclinical Partner(s) will perform toxicology studies in NHPs that are compliant with the FDA’s Good Laboratory Practices (GLP) and International Conference on Harmonization of Technical Requirements for Registration of Pharmaceutical for Human Use (ICH) guidelines. Upon completion of these studies, the CRO will assist the Company with the development of applicable sections of its IND. Objective 2: ADDED Objective 2.2: Complete a second pre-IND Meeting with the FDA. The Company will likely request a second Type B pre-IND meeting with the FDA before end of Year 2. The purpose of this meeting will be to review the data from the GLP-toxicology studies for Ruga-S6 and discuss with the FDA the potential IND filing and ways in which to optimize the design of clinical trials to enable the company to pursue Orphan Drug and accelerated/Breakthrough designation. Objective 3: ADDED Objective 2.3: Perform cGMP manufacturing to generate Ruga-S6 final drug product. The CMO/Partner will perform final development of upstream and downstream manufacturing processes, development and validation of in-process, release, and stability assays, followed by the large-scale manufacturing and cGMP release of clinical material in quantities sufficient to a Phase 1/2 clinical studies. CMO/Partner and the Company currently plan to scale the final manufacturing process to maximum of 1,000L and will perform one full scale, non-cGMP engineering run, followed by one full-scale cGMP run. The final cGMP run, pending the final outcome of cell line development activities in Year 1, will hopefully yield a minimum of 1 gram of Ruga-S6 per liter, or 2 kilograms of drug product for use in clinical trials. Upon completion of these activities and release of drug product, CMO/Partner will assist the Company with developing the CMC section of its IND application. Objective 4 ADDED Objective 2.4: File IND application with the FDA. With assistance from its CRO, CMO, and experienced consultants, the Company will complete and file an IND application with the FDA. This document will provide a comprehensive review of the data generated by the Company in the three required areas of animal pharmacology and toxicology, manufacturing and clinical protocols and enable the Company to commence Phase 1 clinical studies.
Objective 1. To define the trade-off and preliminary design of the DT for small satellites focused on EO applications with: o Survey the opto-mechanical deployment strategies and trade-offs for possible deployment, stabilization, and active optical control techniques relevant to EO scenario [a] for small satellites (Annex A). o Formulate preliminary optical and mechanical design of the DT.